BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Deals

Altacor, Proximagen deal

The companies partnered to develop Proximagen's programs targeting the serotonin (5-HT2C) receptor for ophthalmic indications. Altacor will fund preclinical work of PRX00933, the lead compound under the...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >